Defective interfering influenza virus confers only short-lived protection against influenza virus disease: Evidence for a role for adaptive immunity in DI virus-mediated protection in vivo

Vaccine

Volumn 29, Issue 38, 2011, Pages 6584-6591

  Scott, Paul D ^a   Meng, Bo ^a   Marriott, Anthony C ^a   Easton, Andrew J ^a   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Defective interfering; Immunity; Influenza; Protection; SCID

Indexed keywords

VIROTHERAPY AGENT; VIRUS RNA;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASYMPTOMATIC INFECTION; B LYMPHOCYTE; CONTROLLED STUDY; DEFECTIVE VIRUS; INFLUENZA VIRUS; LETHALITY; MOLECULAR CLONING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REINFECTION; RNA SEQUENCE; SCID MOUSE; T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS GENOME; VIRUS INACTIVATION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; B-LYMPHOCYTES; DEFECTIVE VIRUSES; INFLUENZA A VIRUS; INFLUENZA VACCINES; KILLER CELLS, NATURAL; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, SCID; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES; VIRAL LOAD;

EID: 80051670058     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.114     Document Type: Article

References (49)

1. Holland J.J. Defective viral genomes. Virology 1990, 151-165. Raven Press, New York. 2nd ed. B.N. Fields, D.M. Knipe (Eds.).
2. Holland J.J. Generation and replication of defective viral genomes. Virology 1990, 77-99. Raven Press, New York. 2nd ed. B.N. Fields, D.M. Knipe (Eds.).
3. Huang A.S., Baltimore D. Defective viral particles and viral disease processes. Nature (Lond) 1970, 226:325-327.
4. Perrault J. Origin and replication of defective interfering particles. Curr Top Microbiol Immunol 1981, 93:151-207.
5. Nayak D.P., Chambers T.M., Akkina R.M. Structure of defective-interfering RNAs of influenza virus and their role in interference. The influenza viruses 1989, 269-317. Plenum Press, New York. R.M. Krug (Ed.).
6. Roux L., Simon A.E., Holland J.J. Effects of defective interfering viruses on viral replication and pathogenesis in vitro and in vivo. Adv Virus Res 1991, 40:181-211.
7. Marriott A.C., Dimmock N.J. Defective interfering viruses and their potential as antiviral agents. Rev Med Virol 2010, 20:51-62.
8. Barrett A.D.T., Dimmock N.J. Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol 1986, 128:55-84.
9. Dimmock N.J. The biological significance of defective interfering viruses. Rev Med Virol 1991, 1:165-176.
10. Dimmock N.J. Antiviral activity of defective interfering influenza virus in vivo. Viral and other infections of the respiratory tract 1996, Chapman and Hall, London, p. 421-45. S. Myint, D. Taylor-Robinson (Eds.).
11. von Magnus P. Incomplete forms of influenza virus. Adv Virus Res 1954, 21:59-79.
12. Nayak D.P. Influenza virus defective interfering particles. Ann Rev Microbiol 1980, 34:619-644.
13. Nayak D.P., Chambers T.M., Akkina R.K. Defective-interfering (DI) RNAs of influenza viruses: origin, structure, expression and interference. Curr Top Microbiol Immunol 1985, 114:103-151.
14. Duhaut S.D., Dimmock N.J. Heterologous protection against a lethal human H1N1 influenza virus infection of mice by a H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung. Virology 1998, 248:241-253.
15. Duhaut S., Dimmock N.J. Approximately 150 nt from the 5' end of an influenza A virus segment 1 defective virion RNA are needed for genome stability during passage of defective virus in infected cells. Virology 2000, 275:278-285.
16. Duhaut S.D., Dimmock N.J. Defective segment 1 RNAs that interfere with the production of infectious influenza virus require at least 150 nucleotides of 5' sequence: evidence from a plasmid-driven system. J Gen Virol 2002, 83:403-411.
17. Duhaut S.D., Dimmock N.J. Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and modulates disease. J Virol Meth 2003, 108:75-82.
18. Dimmock N.J., Rainsford E.W., Scott P.D., Marriott A.C. Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral. J Virol 2008, 82:8570-8578.
19. McLain L., Morgan D.J., Dimmock N.J. Protection of mice from lethal influenza by defective interfering virus: T cell responses. J Gen Virol 1992, 73:375-381.
20. McLain L., Dimmock N.J. Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with defective-interfering virus. J Gen Virol 1989, 70:2615-2624.
21. Morgan D.J., Dimmock N.J. Defective interfering virus inhibits immunopathological effects of infectious virus in the mouse. J Virol 1992, 66:1188-1192.
22. Morgan D.J., McLain L., Dimmock N.J. Protection of three strains of mice against lethal influenza in vivo by defective interfering virus. Virus Res 1993, 29:179-193.
23. McLain L., Dimmock N.J. An influenza haemagglutinin-specific IgG enhances class I MHC-restricted CTL killing in vitro. Immunology 1991, 73:12-18.
24. McLain L., Dimmock N.J. A monoclonal antibody produced during infection which recognizes an epitope of influenza hemagglutinin only in the context of H-2k MHC class I antigen. J Immunol 1993, 150:3421-3426.
25. Dimmock N.J., Beck S., McLain L. Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J Gen Virol 1986, 67:839-850.
26. Albert S.E., McKerlie C., Pester A., Edgell B.-J., Carlyle J., Petric M., et al. Time-dependent induction of protective anti-influenza immune responses in human peripheral blood lymphocyte/SCID mice. J Immunol 1997, 159:1393-1403.
27. Bot A., Reichlin A., Isobe H., Bot S., Schulman J., Yokoyama W.M., et al. Cellular mechanisms involved in protection and recovery from influenza virus infection in immunodeficient mice. J Virol 1996, 70:5668-5672.
28. Bunting K.D., Flynn K.J., Riberdy J.M., Doherty P.C., Sorrentino B.P. Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc Natl Acad Sci USA 1999, 96:232-237.
29. Ison M.G., Mishin V.P., Braciale T.J., Hayden F.G., Gubareva L.V. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 2006, 193:765-772.
30. Mozdzanowska K., Feng J., Gerhard W. Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J Virol 2003, 77:8322-8328.
31. Zharikova D., Mozdzanowska K., Feng J.Q., Zhang M.X., Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005, 79:6644-6654.
32. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate by plasmid-based reverse genetics. Virology 2003, 305:192-200.
33. Noble S., Dimmock N.J. Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of type A influenza virus. J Gen Virol 1994, 75:3485-3491.
34. Noble S., McLain L., Dimmock N.J. Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing. Vaccine 2004, 22:3018-3025.
35. Di Trani L., Bedini B., Donatelli I., Campitelli L., Chiappini B., De Marco M.A., et al. A sensitive one-step real-time PCR for detection of avian influenza viruses using a MGB probe and an internal positive control. BMC Infect Dis 2006, 6:87-94.
36. Smith G.L., Hay A.J. Replication of the influenza virus genome. Virology 1982, 118:96-108.
37. Hatada E., Hasegawa M., Mukaigawa J., Shimizu K., Fukuda R. Control of influenza virus gene expresssion: quantitative analysis of each viral RNA species in infected cells. J Biochem 1989, 105:537-546.
38. Weiss B., Schlesinger S. Defective interfering particles of Sindbis virus do not interfere with the homologous virus obtained from persistently infected BHK cells but do interfere with Semliki Forest virus. J Virol 1981, 37:840-844.
39. Rowlands D.J., Grabau E., Spindler K., Jones C., Semler B., Holland J.J. Virus protein changes and RNA termini alterations evolving during persistent infection. Cell 1980, 19:871-880.
40. Holland J.J., Spindler K., Grabau E., Semler B., Jones C., Horodyski F., et al. Viral mutation in persistent infection. ICN-UCLA symposium on molecular and cellular biology animal virus genetics 1980, 695-709. Academic Press, New York. B.N. Fields, R. Jaenisch, C.F. Fox (Eds.).
41. Giachetti C., Holland J.J. Altered replicase specificity is responsible for resistance to defective interfering particle interference of an Sdi- mutant of vesicular stomatitis virus. J Virol 1988, 62:3614-3621.
42. DePolo N., Giachetti C., Holland J.J. Continuing coevolution of virus and defective interfering particles and of viral genome sequences during undiluted passages: virus mutants exhibiting nearly complete resistance to formerly dominant defective interfering particles. J Virol 1987, 61:454-464.
43. Horodyski F.M., Holland J.J. Viruses isolated from cells persistently infected with vesicular stomatitis virus show altered interactions with defective interfering particles. J Virol 1980, 36:627-631.
44. Weiss B., Levis R., Schlesinger S. Evolution of virus and defective-interfering RNAs in BHK cells persistently infected with Sindbis virus. J Virol 1983, 48:676-684.
45. Doherty P.C., Allan W., Eichelberger M., Carding S.R. Roles of alpha/beta and gamma/delta T cell subsets in viral immunity. Ann Rev Immunol 1992, 10:123-151.
46. Gerhard W., Mozdanowska K., Furchner M., Washko G., Maiese K. Role of the B-cell response in the recovery of mice from primary influenza virus infection. Immunol Rev 1997, 159:95-103.
47. Wright P.F., Webster R.G. Orthomyxoviruses. Fields virology 2001, Lippincott, Williams, and Wilkins, Philadelphia, PA, p. 1533-79. 4 ed. D. Knipe, P.M. Howley (Eds.).
48. Noda T., Kawaoka Y. Structure of influenza virus ribonucleoprotein complexes and their packaging into virions. Rev Med Virol 2010, 20:380-391.
49. Easton A.J., Scott P.D., Edworthy N.L., Meng B., Marriott A.C., Dimmock N.J. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine 2011, 29:2777-2784.